



Contents lists available at ScienceDirect

Biochimica et Biophysica Acta

journal homepage: [www.elsevier.com/locate/bbadis](http://www.elsevier.com/locate/bbadis)

## Q2 Metformin and caloric restriction induce an AMPK-dependent restoration of mitochondrial dysfunction in fibroblasts from Fibromyalgia patients

Q3 Elísabet Alcocer-Gómez<sup>a,b</sup>, Juan Garrido-Maraver<sup>b</sup>, Pedro Bullón<sup>a,c</sup>, Fabiola Marín-Aguilar<sup>a</sup>, David Cotán<sup>b</sup>, Angel M. Carrión<sup>d</sup>, José Miguel Alvarez-Suarez<sup>e,f,g</sup>, Francesca Giampieri<sup>h</sup>, José Antonio Sánchez-Alcazar<sup>b</sup>, Maurizio Battino<sup>e,i</sup>, Mario D. Cordero<sup>a,\*</sup>

<sup>a</sup> Research Laboratory, Oral Medicine Department, Universidad de Sevilla, Sevilla, Spain

<sup>b</sup> Centro Andaluz de Biología del Desarrollo (CABD), Universidad Pablo de Olavide-CSIC-Junta de Andalucía and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, 41013 Sevilla, Spain

<sup>c</sup> Dept. of Periodontology, Dental School, University of Sevilla, Spain

<sup>d</sup> División de Neurociencias, Universidad Pablo de Olavide de Sevilla, Carretera de Utrera Km. 1, 41013 Sevilla, Spain

<sup>e</sup> Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche (DISCO)-Sez. Biochimica, Facoltà di Medicina, Università Politecnica delle Marche, Ancona 60131, Italy

<sup>f</sup> Area de Nutrición y Salud, Universidad Internacional Iberoamericana (UNINI), Campeche C.P.24040, Mexico

<sup>g</sup> Facultad de Ciencias de la Salud, Universidad Nacional de Chimborazo, Riobamba, Ecuador

<sup>h</sup> Dipartimento di Scienze Agrarie, Alimentari e Ambientali (D3A), Università Politecnica delle Marche, Via Ranieri 65, Ancona 60131, Italy

<sup>i</sup> Director Centre for Nutrition & Health, Universidad Europea del Atlántico (UEA), Santander 39011, Spain

### 1 7 A R T I C L E I N F O

Article history:  
Received 20 December 2014  
Received in revised form 4 March 2015  
Accepted 7 March 2015  
Available online xxxx

Keywords:  
Fibromyalgia  
AMPK  
Mitochondria  
Oxidative stress  
Metformin  
Caloric restriction

### A B S T R A C T

Impaired AMPK is associated with a wide spectrum of clinical and pathological conditions, ranging from obesity, altered responses to exercise or metabolic syndrome, to inflammation, disturbed mitochondrial biogenesis and defective response to energy stress. Fibromyalgia (FM) is a world-wide diffused musculoskeletal chronic pain condition that affects up to 5% of the general population and comprises all the above mentioned pathophysiological states. Here, we tested the involvement of AMPK activation in fibroblasts derived from FM patients. AMPK was not phosphorylated in fibroblasts from FM patients and was associated with decreased mitochondrial biogenesis, reduced oxygen consumption, decreased antioxidant enzymes expression levels and mitochondrial dysfunction. However, mtDNA sequencing analysis did not show any important alterations which could justify the mitochondrial defects. AMPK activation in FM fibroblast was impaired in response to moderate oxidative stress. In contrast, AMPK activation by metformin or incubation with serum from caloric restricted mice improved the response to moderate oxidative stress and mitochondrial metabolism in FM fibroblasts. These results suggest that AMPK plays an essential role in FM pathophysiology and could represent the basis for a valuable new therapeutic target/strategy. Furthermore, both metformin and caloric restriction could be an interesting therapeutic approach in FM.

© 2015 Elsevier B.V. All rights reserved.

### 1. Introduction

Mitochondria are essential organelles present in virtually all eukaryotic cells. One of the primary functions of mitochondria is ATP production via the oxidative phosphorylation (OXPHOS) pathway. Moreover, they play crucial roles in many other metabolic, regulatory and developmental processes [1]. The involvement of mitochondria in a variety of pathological mechanisms has been partially ascribed to their central role in reactive oxygen species (ROS) production and to the damaging

effect mediated by ROS themselves on the same organelles [2]. In eukaryotic cells, mitochondrial biogenesis is triggered through modulation of the ATP/ADP ratio, activation of adenosine monophosphate activated protein kinase (AMPK) and the subsequent expression of peroxisomal proliferator activator receptor  $\gamma$  co-activator 1 $\alpha$  (PGC-1 $\alpha$ ) and nuclear respiratory factor-1 (NRF1) transcription factors. The AMPK cascade is one of the intracellular pathways that have evolved to ensure that energy homeostasis is maintained even under pathological conditions or stress [3]. AMPK has also been involved in the cellular defense against oxidative stress damage induced by mitochondrial ROS through the increase of MnSOD and catalase expression levels [4].

Fibromyalgia (FM) is a common chronic pain syndrome accompanied by other symptoms such as fatigue, headache, sleep disturbances, and depression. Despite the fact that it affects up to 5% of the general

\* Corresponding author at: Research Laboratory, Oral Medicine Department, Universidad de Sevilla, C/Avicena s/n, 41009 Sevilla, Spain. Tel.: +34 954 481120; fax: +34 954 486784.

E-mail address: [mdcormor@us.es](mailto:mdcormor@us.es) (M.D. Cordero).

population worldwide, its pathogenic mechanism remains elusive. Because not all FM patients have a mitochondrial dysfunction, it has recently been hypothesized that oxidative stress and mitochondrial dysfunction may be important events in pathogenesis of a subgroup of FM patients [5–9]. There is evidence supporting this hypothesis, and thus, reduced mitochondrial mass and impaired bioenergetics have been described in blood cells derived from FM patients [8–10]. Furthermore, different antioxidant enzymes have been observed to be drastically reduced in FM patients [5–7,9,11]. Recently, we have also found reduced AMPK gene expression levels in blood mononuclear cells (BMCs) from FM patients [9].

As AMPK has a central regulatory role in cell metabolism, mitochondrial biogenesis and oxidative stress response, we evaluate if AMPK down-regulation could be at least in part responsible for the impaired oxidative stress response and mitochondrial dysfunction observed in FM. Here, we assessed this hypothesis in cultured skin fibroblasts from patients enrolled in a trial concerning the study of inflammation and mitochondrial dysfunction in BMCs (all patients had mitochondrial dysfunction in BMCs) [8].

## 2. Material and methods

### 2.1. Ethical statements

The approval of the ethical committee of the University of Seville was obtained, according to the principles of the Declaration of Helsinki and all the International Conferences on Harmonization and Good Clinical Practice Guidelines. All participants in the study gave their written informed consent before initiating it.

### 2.2. Patients

The inclusion criterion was Fibromyalgia, based on current ACR diagnostic criteria [9], and diagnosed 2 to 3 years previously. The clinical characteristics of each group are shown in Supplementary Table 1. Exclusion criteria were: acute infectious disease within the previous 3 weeks; past or present neurological, psychiatric, metabolic, autoimmune, allergy-related, dermal or chronic inflammatory disease; undesired habits (e.g., smoking and alcohol); medical conditions that required glucocorticoid treatment, analgesics or antidepressant drugs; past or current substance abuse or dependence; pregnancy or current breastfeeding. Three FM female patients and two healthy female volunteers matched for age range, gender, ethnicity and demographic features (completion of at least 9 years of education and member of the middle socioeconomic class), were included in the study. Healthy controls had no signs or symptoms of FM and had not taken any medication for at least 3 weeks prior to commencing the study. None of the patients or controls had taken any drug or vitamin/nutritional supplements during the 3 weeks prior to blood sample collection. All patients and controls followed a standard balanced diet (carbohydrate 50–60%, protein 10–20% and fat 20–30%) for 3 weeks prior to blood collection, as established by a diet program. Clinical data were obtained from a physical examination and subjects were evaluated using the Fibromyalgia Impact Questionnaire (FIQ), the visual analogues scale (VAS) and depression with the Beck Depression Inventory (BDI). Tender points were identified by digital pressure at the 18 locations recommended by ACR which included a minimum of 11 out of 18. Coagulated blood samples were collected from patients and controls after 12 h fasting, centrifuged at 3800  $\times$ g for 5 min, and the serum was stored at  $-80^{\circ}\text{C}$  until testing. Serum biochemical parameters were assayed by routine analytical methods. Routine laboratory test yielded normal results for glucose, uric acid, creatine kinase, aspartate aminotransferase, alanine aminotransferase, cholesterol, and triglycerides (Supplementary Table 2).

### 2.3. Reagents

Trypsin and metformin were purchased from Sigma Chemical Co., (St. Louis, Missouri). Monoclonal Antibodies specific for mitochondrial respiratory chain complex subunits [Anti-human Complex I (39 kDa subunit), Complex II (30 kDa subunit I), Complex III (Core 1 subunit and Complex IV (COX II)], Mitosox<sup>TM</sup>, PicoGreen, and Hoechst 3342, were purchased from Invitrogen/Molecular Probes (Eugene, Oregon). Anti-cytochrome c antibodies were purchased from PharMingen (BD Bioscience, San Jose, California). Anti-GAPDH monoclonal antibody, clone 6C5, was purchased from Research Diagnostic, Inc., (Flanders, New Jersey). Complex I 8 kDa subunit and Complex II 70 kDa subunit, anti-PGC1- $\alpha$  and OGG-1 antibodies were from Abcam (Cambridge, UK); anti-AMPK-p antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); and MnSOD antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). A cocktail of protease inhibitors (complete cocktail) was purchased from Boehringer Mannheim (Indianapolis, IN). The ImmunoStar HRP substrate kit was from Bio-Rad Laboratories Inc. (Hercules, CA).

### 2.4. Caloric restriction assay

For all experiments, only male mice were used. Eight-week-old male C57/BL6/J mice weighing 25–30 g were maintained on a 12 h light/dark cycle. All studies were performed in accordance with the European Union guidelines (86/609/EU) and Spanish regulations for the use of laboratory animals in chronic experiments (BOE 67/8509-12, 1988). All experiments were approved by the local institutional animal care committee. Calorie restriction (CR) regimen was progressively implemented: it was initiated with 10% restriction diet during the first week, followed by 20 and 30% during the second and third weeks, respectively, and maintained at 30% until the end of treatment. After testing, mice were sacrificed by decapitation. Blood samples were collected frozen at  $-80^{\circ}\text{C}$ . In several experiments, fibroblasts were cultured using 10% mice serum fed *ad libitum* (AL) or CR. Cells were incubated at  $37^{\circ}\text{C}$  in a 5%  $\text{CO}_2$  atmosphere. Serum was heat activated for 30 min at  $55^{\circ}\text{C}$ .

### 2.5. Behavioral assays

Behavioral analyses were performed in a testing room with homogeneous noise and light levels. The testing apparatus was cleaned with 70% ethanol (Panreac Química S.A.U.) between trials to eliminate any influence of animal odor on the exploratory behavior.

### 2.6. Pain assay

For the hot-plate test, a glass cylinder (16 cm high, 16 cm in diameter) was used to constrain the mice to the heated surface of the plate. The plate surface was maintained at  $50\text{--}55 \pm 0.5^{\circ}\text{C}$  and the latency to paw-licking was measured, with a cut-off of 30 s.

### 2.7. Fibroblast cultures

Control fibroblasts were human primary fibroblasts from healthy volunteers. Samples from patients and controls were obtained according to the Helsinki Declarations of 1964, as revised in 2001. Fibroblasts were cultured in DMEM media (4500 mg/L glucose, L-glutamine, piruvate), (Gibco, Invitrogen, Eugene, OR, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen, Eugene, OR, USA) and antibiotics (Sigma Chemical Co., St. Louis, MO, USA). Cells were incubated at  $37^{\circ}\text{C}$  in a 5%  $\text{CO}_2$  atmosphere.

## 183 2.8. Treatment

184 2 mM metformin (Sigma Aldrich) and/or 100  $\mu$ M of H<sub>2</sub>O<sub>2</sub> at 48 h  
185 were used for *in vitro* experiments.

## 186 2.9. Mitochondrial respiratory chain enzyme activities

187 Activities of NADH:coenzyme Q1 oxidoreductase (complex I),  
188 succinate deshydrogenase (complex II), ubiquinol:cytochrome c oxidore-  
189 ductase (complex III), cytochrome c oxidase (complex IV), NADH: cyto-  
190 chrome c reductase (complex I + III), succinate:cytochrome c reductase  
191 (complex II + complex III) and citrate synthase (CS) were determined  
192 in sonicated-permeabilized fibroblasts using spectrophotometric  
193 methods. Results are expressed as Units/CS (mean  $\pm$  SD). Proteins of  
194 fibroblast homogenates were analyzed by the Lowry procedure.

## 195 2.10. Western blotting

196 Whole cellular lysate from fibroblasts was prepared by gentle shak-  
197 ing with a buffer containing 0.9% NaCl, 20 mMTris-ClH, pH 7.6, 0.1% tri-  
198 ton X-100, 1 mM phenylmethylsulfonylfluoride and 0.01% leupeptine.  
199 Electrophoresis was carried out in a 10–15% acrylamide SDS/PAGE.  
200 Proteins were transferred to Immobilon membranes (Amersham  
201 Pharmacia, Piscataway, NJ). Mouse anti-Complex I (8 and 39 kDa sub-  
202 unit), mouse anti-complex II (30 kDa subunit I), mouse anti-Complex  
203 III (Core 1 subunit), mouse anti-complex IV (COX II), AMPK-P, PGC-1  
204  $\alpha$ , MnSOD, catalase and DNA repair enzyme 8-oxoguanine DNA  
205 glycolase-1 (OGG-1) antibodies were used to detect proteins by West-  
206 ern blotting. Proteins were electrophoresed, transferred to nitrocellu-  
207 lose membranes and, after blocking over night at 4 °C, incubated with  
208 the respective antibody solution, diluted at 1:1000. Membranes were  
209 then probed with their respective secondary antibody (1:2500).  
210 Immunolabeled proteins were detected by using a chemiluminescence  
211 method (Immun Star HRP substrate kit, Bio-Rad Laboratories Inc.,  
212 Hercules, CA). Protein was determined by the Bradford method.

## 213 2.11. Measurement of CoQ levels

214 CoQ levels in cultured fibroblasts were performed using a method  
215 previously described by our group [8].

## 216 2.12. Antioxidant enzyme activity

217 Catalase activity was determined in cellular lysate by monitoring  
218 H<sub>2</sub>O<sub>2</sub> decomposition at 240 nm [12]. SOD activity was determined on  
219 the basis of the inhibition of the formation of NADH–phenazine  
220 methosulfate–nitroblue tetrazolium formazan [13].

## 221 2.13. Quantification of mtDNA

222 Nucleic acids were extracted from fibroblasts by standard cellular  
223 lysis. The primers used were: mtF3212 (5'-CACCAAGAACAGGGTTT  
224 GT-3') and mtR3319 (5'-TGGCCATGGGTATGTTGTTAA-3') for mtDNA,  
225 and, 18S rRNA gene 18S1546F (5'-TAGAGGGACAGTGGCGTTC-3')  
226 and 18S1650R (5'-CGCTGAGCCAGTCAGTGT3') for nDNA for loading  
227 normalization. Arbitrary units were computed as the ratio between  
228 the optical density band corresponding to the mtDNA studied in the  
229 20–30th cycle and that of the nDNA in the 15th amplification cycle.  
230 One unit was considered to be the ratio corresponding to the control pa-  
231 tient. For imaging of mtDNA in living cells, control and FM fibroblasts  
232 cells were cultured in dishes with a glass bottom (MatTek Corporation,  
233 Ashland, MA) and stained with PicoGreen (3  $\mu$ L/mL) for 1 h at 37 °C.  
234 TMRM (100 nM) staining was used to visualize mitochondria.

## 2.14. Mitochondrial ROS production

235 Mitochondrial ROS generation in BMCs and fibroblasts were  
236 assessed by MitoSOX™ Red, a red mitochondrial superoxide indicator.  
237 MitoSOX Red is a novel fluorogenic dye recently developed and validat-  
238 ed for highly selective detection of superoxide in the mitochondria of  
239 live cells. MitoSOX™ Red reagent is live-cell permeant and is rapidly  
240 and selectively targeted to the mitochondria. Once in the mitochondria,  
241 MitoSOX™ Red reagent is oxidized by superoxide and exhibits red  
242 fluorescence.  
243

## 2.14.1. Fluorescence microscopy

244 Cells grown on microscope slides in 6-well plates for 24 h were incu-  
245 bated with MitoSOX™ Red for 30 min at 37 °C, washed twice in PBS,  
246 fixed with 4% paraformaldehyde in PBS for 0.5–1 h at room tempera-  
247 ture, and washed twice with PBS. After that, cells were incubated for  
248 10 min at 37 °C with anti-cytochrome c antibody (Invitrogen, Barcelona,  
249 Spain) to label mitochondria. Slides were analyzed by immunofluores-  
250 cence microscopy.  
251

## 2.14.2. Flow cytometry

252 Approximately  $1 \times 10^6$  cells were incubated with 1  $\mu$ M MitoSOX™  
253 Red for 30 min at 37 °C, washed twice with PBS, resuspended in  
254 500  $\mu$ L of PBS and analyzed by flow cytometry in an Epics XL cytometer,  
255 Beckman Coulter, Brea, California, USA (excitation at 510 nm and fluo-  
256 rescence detection at 580 nm).  
257

## 2.15. Oxygen consumption rate (OCR)

258 The oxygen consumption rate (OCR) was assessed in real-time using  
259 the 24 well Extracellular Flux Analyzer XF-24 (Seahorse Bioscience,  
260 North Billerica, MA, USA) according to the manufacturer's protocol,  
261 which allows measuring OCR changes after up to four sequential addi-  
262 tions of compounds. Cells ( $5 \times 10^4$ /well) were seeded for 16 h in the  
263 XF-24 plate before the experiment in a DMEM/10% serum medium  
264 and then incubated for 24 h with the different compounds studied.  
265 Before starting measurements, cells were placed in a running DMEM  
266 medium (supplemented with 25 mM glucose, 2 mM glutamine, 1 mM  
267 sodium Pyruvate, and without serum) and pre-incubated for 20 min  
268 at 37 °C in the absence of CO<sub>2</sub> in the XF Prep Station incubator (Seahorse  
269 Bioscience, Billerica MA, USA). Cells were transferred to an XF-24 Extra-  
270 cellular Flux Analyzer and after an OCR baseline measurement a profil-  
271 ing of mitochondrial function was performed by sequential injection  
272 of four compounds that affect bioenergetics, as follows: 55  $\mu$ L of  
273 oligomycin (final concentration 2.5  $\mu$ g/mL) at injection in port A, 61  $\mu$ L  
274 of 2,4-dinitrophenol (2,4-DNP) (final concentration 1 mM) at injection  
275 in port B, and 68  $\mu$ L of antimycin/rotenone (final concentration 10  $\mu$ M/  
276 1  $\mu$ M) at injection in port C. A minimum of five wells was utilized per  
277 condition in any given experiment. Data are expressed as pMol of O<sub>2</sub> con-  
278 sumed per minute normalized to 1000 cells (pMol O<sub>2</sub>/1000 cells/min).  
279

## 2.16. Lipid peroxidation

280 Fibroblasts were cultured on coverslips and incubated with 1  $\mu$ M  
281 C11-Bodipy (BODIPY® 581/591 C11) for 30 min at 37 °C. Coverslips  
282 were then rinsed with PBS and mounted onto slides as described  
283 above for analysis with a fluorescence microscope. Fluorescent intensity  
284 was measured using the Image J software (National Institutes of Health,  
285 Bethesda, Maryland, USA).  
286

287 Lipid peroxidation in serum from mice was detected by measuring  
288 the concentration of TBARS in fluorescence at 532 nm (F7000, HITACHI),  
289 using a TBARS detection kit according to the manufacturer's instruc-  
290 tions. Absorbance of was measured at 535 nm. TBARS concentrations  
291 of the samples were calculated using the extinction co-efficient of  
292  $156,000 \text{ M}^{-1} \text{ cm}^{-1}$ .  
293

## 2.17. PCR Amplification and mtDNA sequencing


The complete mtDNA was amplified from total DNA in 24 overlapping 800–1000-bp-long PCR fragments. Primers were carefully designed using the revised human mtDNA Cambridge reference sequence ([www.mitomap.org/mitoseq.html](http://www.mitomap.org/mitoseq.html)).

The PCR fragments were sequenced in both strands in an ABI 3730 (Applied Biosystems; [www.appliedbiosystems.com](http://www.appliedbiosystems.com); Foster City, CA) sequencer using a BigDye v3.1 sequencing kit (Applied Biosystems; [www.appliedbiosystems.com](http://www.appliedbiosystems.com); Foster City, CA). Assembly and identification of variations in the mtDNA were

carried out using the Staden package. For this purpose the revised human mtDNA Cambridge reference sequence ([www.mitomap.org/mitoseq.html](http://www.mitomap.org/mitoseq.html)) was used. The whole process was carried out at Secugen (Madrid, Spain).


## 2.18. Analysis of apoptosis and viable cells

Viable cells were determined from their normal cell and nuclear morphology and exclusion of propidium iodide. In each case 10 random fields and more than 500 cells were counted.



**Fig. 1.** Mitochondrial dysfunction in skin fibroblasts from FM patients. (A) Mitochondrial enzymatic activities were determined as described in [Material and methods](#). Results (mean  $\pm$  SD) are expressed in U/Cs (units per citrate synthase). (B) Protein expression levels of mitochondrial subunits of complex I, II, III and complex IV. (C) Protein levels were determined by densitometric analysis (IOD, integrated optical intensity) of three different Western blots and normalized to GADPH signal, using fibroblasts from three representative FM patients, compared with a pool of fibroblasts from 5 healthy age- and sex-matched control subjects. \* $P < 0.001$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.05$  between control and FM patients.





**Fig. 2.** Abnormalities in various aspects of bioenergetic function of mitochondria. Oxygen consumption rate (OCR) in cells from control and FM patients. (A) OCR was monitored using the Seahorse XF-24 Extracellular Flux Analyzer with the sequential injection of oligomycin (1  $\mu$ g/mL), 2,4-DNP (100  $\mu$ M), rotenone (1  $\mu$ M) at the indicated time point (B) The basal OCR was markedly affected in cells from FM compared to control. (C) The spare respiratory capacity (SRC) of FM fibroblasts showed a significant decrease with respect to control fibroblasts. (D) CoQ<sub>10</sub> levels in control and FM cells. (E) mtDNA copy number was measured by RT-PCR as described in [Material and methods](#). (F and G) mtDNA imaging by PicoGreen staining and quantification of PicoGreen foci in control and FM fibroblasts. For the control cells, data are the means  $\pm$  SD for experiments performed on two different control cell lines. Data represent the mean  $\pm$  SD of three separate experiments. Bar = 15  $\mu$ m. \* $P$  < 0.001; \*\* $P$  < 0.01 between control and FM patients.


## 2.19. Statistical analysis

Data in figures is given as mean  $\pm$  SD. Data between different groups were analyzed statistically by using ANOVA on Ranks with Sigma Plot and Sigma Stat statistical software (SPSS for Windows, 19, 2010, SPSS Inc. Chicago, IL, USA). For cell-culture studies, Student's *t* test was used for data analyses. A value of  $P < 0.05$  was considered significant.

## 3. Results

## 3.1. Mitochondrial metabolism

As AMPK signaling has been previously reported to be altered in BMCs from FM patients [9], we have next studied the role of AMPK in FM pathophysiology using isolated fibroblasts from three representative FM



**Fig. 3.** Oxidative stress and oxidative damage levels in fibroblasts from FM patients. (A) Mitochondrial ROS production was analyzed in BMCs from control and FM patients by flow cytometry as described in Material and Methods. (B) Quantification of lipid peroxidation in control and FM fibroblasts. Data represent the oxidized lipid/reduced lipid ratio. Data represent the mean  $\pm$  SD of three separate experiments. \* $P < 0.001$ , <sup>a</sup> $P < 0.01$  between control and FM patients. (C) Protein expression levels of 8-oxoguanine glycosylase (OGG-1, a DNA glycosylase enzyme responsible for the excision of 7,8-dihydro-8-oxoguanine (8-oxoG)). (D) Mitochondrial ROS generation in fibroblasts cultured for 72 h in normal growth medium prior to analysis. MitoSOX Red staining revealed increased superoxide anion. MitoSOX Red colocalized with subunit II of cytochrome c oxidase (COX II) in merged images, indicating that superoxide anion production was mainly in mitochondria. (E) Lipid peroxidation in control and FM fibroblasts using C11-Bodipy staining. Red fluorescence represents non-oxidized lipids, and green fluorescence represents oxidized lipids. Scale bar 30  $\mu$ m.

patients. FM fibroblasts displayed a significant reduction in the activities of mitochondrial respiratory enzymes compared to control fibroblasts (Fig. 1A). Mitochondrial protein expression levels correlated with the depressed activities found in respiratory enzymes (Fig. 1B). Next, we investigated mitochondrial function by measuring the OCR values in control and FM fibroblasts, exposed sequentially to each of four modulators of oxidative phosphorylation (OXPHOS): oligomycin (an inhibitor of F1Fo-ATPase or complex V), 2,4-DNP (uncoupling of the OXPHOS electron transport chain) and antimycin/rotenone (complex I and III inhibitors respectively) (Fig. 2A). The basal OCR was markedly affected in fibroblasts from FM patients compared to controls (Fig. 2B). The spare respiratory capacity (SRC) of cells was obtained by calculating the mean of OCR values after injection of 2,4-DNP minus the basal respiration and could be used as an indicator of how close a cell is operating to its bioenergetic limit. Fibroblasts from FM patients showed a significant decrease of SRC compared to control cells (Fig. 2C). Furthermore, similarly to what was previously found in BMCs [8], FM fibroblasts also showed decreased CoQ<sub>10</sub> levels when compared to controls (Fig. 2D). CoQ<sub>10</sub> content of fibroblasts from patient 1 was reduced by 70%, from patient 2 by 78% and from patient 3 by 82%. FM fibroblasts also had a smaller number of mitochondria; we measured mtDNA content and compared it with control values. Results showed that mtDNA content was 30–50% lower in fibroblasts from FM (Fig. 2E). This finding was further confirmed by visualizing the number of mtDNA nucleoids per cell using PicoGreen staining and fluorescence microscopy. Mitochondrial nucleoids were significantly reduced in FM fibroblasts (Figs. 2F and G).

Since mitochondrial respiratory chain defects are usually associated with mtDNA mutations or deletions, we next sequenced the complete mtDNA from FM patients. Sequence analysis did not show any important alterations as mutations or deletions which could justify the mitochondrial defects. We only found mitochondrial polymorphisms which are also observed in control fibroblasts (Table S1).


### 3.2. AMPK is implicated in oxidative stress response in FM

Mitochondrial superoxide production was significantly increased in FM fibroblasts compared to controls ( $P < 0.001$ ), accompanied by high levels of lipid peroxidation (Figs. 3A, B, D and E). To confirm these results, the expression of an additional oxidative stress marker such as 8-oxoguanine glycosylase (OGG1) was also determined. FM fibroblasts showed high levels of OGG1 (Fig. 3C).


As AMPK induces PGC-1 $\alpha$  phosphorylation which leads to increased antioxidant enzymes expression levels and mitochondrial biogenesis, we analyzed AMPK protein expression levels and activation in FM fibroblasts. Results showed low expression levels of active phosphorylated AMPK, PGC-1 $\alpha$  and MnSOD (Fig. 4A), suggesting that AMPK-dependent activation of PGC-1 $\alpha$  was indeed impaired in FM fibroblasts. As reduced antioxidant enzyme levels have been previously described in FM [5,6,11], we next investigated the response to moderate oxidative stress induced by exogenous addition of H<sub>2</sub>O<sub>2</sub> in FM fibroblasts. Incubation of FM fibroblasts with H<sub>2</sub>O<sub>2</sub> failed to activate AMPK and PGC-1 $\alpha$  and to increase MnSOD expression levels (Fig. 4A). As a consequence of an impaired defensive response to oxidative stress, cell death increased in FM fibroblasts treated with H<sub>2</sub>O<sub>2</sub> (Fig. 4B).

Under oxidative stress condition, AMPK was found to lead to an increase in the NADPH generation [14]. However, as FM fibroblasts had reduced activity of phosphorylated AMPK, we found low levels of NADPH. Interestingly, metformin, an AMP mimetic that directly activates AMPK, induced an increase of NADPH levels and the activity of SOD and catalase (Figs. 5A–C).

FM fibroblasts under moderate oxidative stress conditions mediated by H<sub>2</sub>O<sub>2</sub> treatment or induction of AMPK by metformin showed PGC-1 $\alpha$  activation (Fig. 5D) which increased protection against H<sub>2</sub>O<sub>2</sub> exposure and reduced cell death (Fig. 5E). These results suggest that the induction of AMPK phosphorylation could be an interesting



**Fig. 4.** Comparison of oxidative stress levels and metabolic response to H<sub>2</sub>O<sub>2</sub> treatment of skin fibroblasts between FM patients and healthy subjects. (A) Protein expression levels of phosphorylated AMPK, PGC-1 $\alpha$ , and MnSOD after incubation with 100 mM H<sub>2</sub>O<sub>2</sub> for 48 h. Protein levels were determined by densitometric analysis (IOD, integrated optical intensity) of three different Western blots and normalized to GAPDH signal. \* $P < 0.001$  between control and FM patients. (B) Percentage of apoptosis in control and FM fibroblasts after incubation with 100 mM H<sub>2</sub>O<sub>2</sub> for 48 h. \* $P < 0.001$  between control and FM patients.




**Fig. 5.** Effects of metformin treatment on antioxidant defense and oxidative stress response of fibroblasts from FM patients. (A, B and C) NADPH levels and antioxidant enzymes SOD and catalase (CAT) activities in FM fibroblasts treated with metformin (Met). \* $P < 0.001$  and \*\* $P < 0.05$  between control and control with Met. <sup>a</sup> $P < 0.001$  and <sup>aa</sup> $P < 0.005$  between FM and control. <sup>#</sup> $P < 0.001$  between FM and FM with Met. (D) Levels of phosphorylated PGC- $\alpha$  in FM fibroblasts after 100 mM H<sub>2</sub>O<sub>2</sub> and 2 mM Met treatments for 48 h (representative subset is shown). (E) Percentage of apoptosis in control and FM fibroblasts after incubation with 100 mM H<sub>2</sub>O<sub>2</sub> and 2 mM Met for 48 h. \* $P < 0.001$  between control and FM patients and between H<sub>2</sub>O<sub>2</sub> and H<sub>2</sub>O<sub>2</sub> + Met.

therapeutic approach in FM. Given that it has been speculated that the beneficial effects of caloric restriction (CR) could be mediated by AMPK [3], CR could be a promising method to alleviate oxidative damage in FM. Taken into account the possible role of AMPK in FM pathophysiology and the results with metformin treatment, we next studied the implication of AMPK in the protective effect of CR on FM fibroblasts.

Thus, we performed an experiment with a mouse model of CR. Several mice were fed with a normal diet and with CR for one month. Mice submitted to the CR diet for one month developed a marked analgesia

when compared with *ad libitum* (AL) fed mice (Fig. 6A) accompanied by AMPK phosphorylation (Fig. 6B) and reduced levels of serum oxidative stress (Fig. 6C). To determine the potential effect of improvement of AMPK by CR, fibroblasts from FM patients were cultured with serum from AL and CR mice, and cell growth, ATP and mitochondrial mass were assessed. Serum from CR mice improved cell growth in controls and FM fibroblasts (Fig. 6D), accompanied by an increase in ATP levels and mitochondrial mass (determined by increased citrate synthase activity) and cell morphology normalization (Figs. 6E–G).





**Fig. 6.** Effects of caloric restriction on bioenergetics function of mice and skin fibroblasts from FM patients. (A) Evolution of pain sensitivity in *ad libitum* (AL) and caloric restriction (CR) mice evaluated in the hot plate test at 55 °C. (B) Phosphorylation of AMPK after CR. (C) Oxidative stress in serum evaluated by TBARS levels. (D) Cell growth with AL and CR serum determined in healthy and FM fibroblasts. (E) Morphological changes of fibroblasts incubated with FBS or serum from AL or CR mice. (F) ATP levels in control and FM fibroblasts. (G) Mitochondrial mass determined by measuring citrate synthase levels and cytochrome c levels by immunofluorescence in control and FM fibroblasts. Data represents the means  $\pm$  SD of three separate experiments. \* $P < 0.001$  AL or CR; \*\* $P < 0.01$  between AL or CR in control fibroblasts.

#### 4. Discussion

Despite decades of intense research, the basic pathophysiological mechanisms of FM still remain elusive. Several important pathophysiological processes in FM onset and development have been described: oxidative stress, mitochondrial dysfunction, bioenergetic alterations and inflammation processes are only some of the most important mechanisms that have been postulated [5–11]. AMPK has been reported to play a master regulatory role in all these cellular processes and its dysregulation has been described in several other diseases [15]. Recently, we have reported alterations in AMPK signaling in BMCs from FM patients. However, the role of AMPK in FM remains unknown. In this study, we found a marked mitochondrial dysfunction in fibroblasts derived from 3 FM patients. It is interesting to remark that until now, all the studies in FM have explored the pathophysiological processes only in biological samples isolated directly from patients, e.g. BMCs, platelets, serum, plasma, saliva, muscle. In this work we have used human dermal fibroblasts that have a long track record of utility in mitochondrial

disease biochemistry and molecular studies [1]. Skin fibroblasts represent a useful biological model in which defined mutations and the cumulative cellular damage can be examined. We found reduced mitochondrial chain enzymatic activities and proteins, CoQ<sub>10</sub> levels, mitochondrial mass and ATP levels, accompanied by increased oxidative damage. We found no specific mutation after mtDNA sequencing; however, we cannot rule out the presence of mutations in nDNA or potential mtDNA mutations in other patients not included in this study.

Moreover, we observed reduced levels of phosphorylated PGC-1 $\alpha$  accompanied by low levels of antioxidant MnSOD and impaired oxidative stress response which are protective mechanisms controlled by AMPK. Furthermore, reduced levels of active phosphorylated AMPK were observed in FM fibroblasts. These data are interesting because AMPK has been involved in the control of peripheral sensitization of nociceptors, providing evidence of AMPK activation as a novel treatment avenue for acute and chronic pain states [16]. In addition, the exposition of fibroblasts to moderate oxidative stress, as induced by exogenously added H<sub>2</sub>O<sub>2</sub>, fails to up-regulate AMPK, PGC-1 $\alpha$  and

antioxidant enzymes. Concerning this, AMPK has been deeply involved in the regulation of oxidative stress and mitochondrial dysfunction [17–19]. In this sense, AMPK phosphorylation by metformin treatment induced activation of PGC-1 $\alpha$  accompanied by increased antioxidant enzyme activities and, as a consequence, protection of FM fibroblasts against stress exposure. PGC-1 $\alpha$  is a key player in the ROS-induced mitochondrial biogenesis, along with the NRF-1 and the mitochondrial transcription factor Tfam [20]. According to our data, metformin could induce PGC-1 $\alpha$  activation by AMPK phosphorylation. Furthermore, PGC-1 $\alpha$  has a key role in the antioxidant enzymes biosynthesis, and its genetic deletion has shown an inhibitory effect in SOD2 and catalase expression levels [4,20]. Furthermore, it has been shown that PGC-1 $\alpha$  induction by phosphorylation of AMPK increases SOD2 and catalase expression levels [21]. Our data show that PGC-1 $\alpha$  activation by metformin induces increased mitochondrial biogenesis and antioxidant enzymes expression levels, and, as a consequence, a more physiological response to oxidative stress. A chronic exposure to oxidative stress and dysregulation of the stress response are accepted causative factors involved in the pathophysiology of FM [11,22–24]. Our results could represent the basis for a valuable new therapeutic target/strategy. We found in FM fibroblasts: (i) a lack of AMPK phosphorylation and (ii) restoration of its phosphorylation by AMPK activators, such as metformin. These findings suggest that AMPK plays a central role in FM pathophysiology and stress response. Identification of AMPK as a regulating factor in FM would have implications for patient management and treatment. We can hypothesize that the loss of sensitivity of AMPK activation is responsible for increased oxidative stress and impaired bioenergetics in FM patients. Furthermore, other metabolic events have been related with AMPK down-regulation. Reduced AMPK activity has been found in obesity or metabolic syndrome [3], both reported to be implicated in FM [25,26]. AMPK dysfunction seems to explain many of the pathophysiological alterations found in FM. In this sense, activation of AMPK with other activators having similar effects to metformin must induce similar beneficial effects. To investigate whether AMPK could be responsible for the ability of CR to improve the cells of FM patients, we used an *in vitro* cell culture model that recapitulates key *in vivo* proliferative and phenotypic features of CR [27]. In this model, cells from patients were cultured in the presence of serum from caloric restricted mice resulting in an important improvement in FM fibroblasts alterations. Future research should be focused on studying the significance of AMPK in FM etiology and as a therapeutic target. Furthermore, an important challenge in FM is the moderate effectiveness of pharmacological therapies; in this sense, AMPK activators, such as AICAR, metformin, CoQ<sub>10</sub>, resveratrol, CR or physical activity, can provide new therapeutic opportunities [3]. As not all patients have a mitochondrial dysfunction, our results could help to characterize a subgroup of patients in which mitochondrial target treatment could be the most appropriate strategy. In this sense, mitochondrial protector drugs or mitochondrial biogenesis activators may also be considered as new possible therapeutic approach in FM. Nevertheless, more research is needed in order to establish a possible primary causation link between AMPK and FM.

The results described in this article could serve as a new way of designing experiments to better understand the influence of oxidative stress on the development of FM and generate new therapeutic strategies.

## Abbreviations

AL	<i>ad libitum</i>
CAT	catalase
CoQ <sub>10</sub>	Coenzyme Q <sub>10</sub>
CR	caloric restriction
FBS	fetal bovine serum
FM	Fibromyalgia
HPLC	high-performance liquid chromatography
Met	metformin
OCR	oxygen consumption rate

OGG1	8-oxoguanine glycosylase	502
PGC-1 $\alpha$	peroxisomal proliferator activator receptor $\gamma$ co-activator 1 $\alpha$	503
NRF1	nuclear respiratory factor-1	504
ROS	reactive oxygen species	505
SOD	superoxide dismutase	506
TBARS	thiobarbituric acid reactive substances	508

## Author disclosure statement

All the Authors declare that no conflict of interest exists for any of them.

## Author contributions

E.A.G. and M.D.C. conceived of the study and wrote the manuscript. A.M.C., E.A.G., F.M.A., and DC. performed mouse experiments. E.A.G., J.G.M., J.M.A.S., F.G. P.B. and J.A.S.A. performed cell culture experiments. J.A.S.A. conducted patient evaluations and skin biopsies isolation. All authors analyzed and discussed the data and commented on the manuscript.

## Acknowledgments

This work has been supported by Federación Andaluza de Fibromialgia y Fatiga Crónica (ALBA Andalucía) and Grupo de Investigacion Junta de Andalucía CTS113. Authors are indebted with Ms Monica Glebocki for extensive editing of the manuscript.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.bbadis.2015.03.005>.

## References

- [1] R.H. Haas, S. Parikh, M.J. Falk, R. Saneto, N.I. Wolf, N. Darin, L.J. Wong, B.H. Cohen, R.K. Naviaux, The in-depth evaluation of suspected mitochondrial disease, *Mol. Genet. Metab.* 94 (2008) 16–37.
- [2] J.F. Turrens, Mitochondrial formation of reactive oxygen species, *J. Physiol.* 552 (2003) 335–441.
- [3] G.R. Steinberg, B.E. Kemp, AMPK in health and disease, *Physiol. Rev.* 89 (2009) 1025–1078.
- [4] S.L. Colombo, S. Moncada, AMPK $\alpha$ 1 regulates the antioxidant status of vascular endothelial cells, *Biochem. J.* 421 (2009) 163–169.
- [5] O. Altindag, H. Celik, Total antioxidant capacity and the severity of the pain in patients with fibromyalgia, *Redox Rep.* 11 (2006) 131–135.
- [6] S. Bagis, L. Tamer, G. Sahin, R. Bilgin, H. Guler, B. Ercan, C. Erdogan, Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? *Rheumatol. Int.* 25 (2005) 188–190.
- [7] S. Ozgocmen, H. Ozyurt, S. Sogut, O. Akyol, Current concepts in the pathophysiology of fibromyalgia: the potential role of oxidative stress and nitric oxide, *Rheumatol. Int.* 26 (2006) 585–597.
- [8] M.D. Cordero, E. Díaz-Parrado, A.M. Carrión, S. Alfonsi, J.A. Sánchez-Alcazar, P. Bullón, M. Battino, M. de Miguel, Is inflammation a mitochondrial dysfunction-dependent event in fibromyalgia? *Antioxid. Redox Signal.* 18 (2013) 800–807.
- [9] M.D. Cordero, E. Alcocer-Gómez, M. de Miguel, O. Culic, A.M. Carrión, J.M. Alvarez-Suarez, P. Bullón, M. Battino, A. Fernández-Rodríguez, J.A. Sánchez-Alcazar, Can coenzyme Q10 improve clinical and molecular parameter in fibromyalgia? *Antioxid. Redox Signal.* 19 (2013) 1356–1361.
- [10] L. Bazzichi, G. Giannaccini, L. Betti, L. Fabbri, L. Schmid, L. Palego, C. Giacomelli, A. Rossi, L. Giusti, F. De Feo, T. Giuliano, G. Mascia, S. Bombardieri, A. Lucacchini, ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia, *Clin. Biochem.* 41 (2008) 1084–1090.
- [11] M. Neyal, F. Yimenicioglu, A. Aydeniz, A. Taskin, S. Saglam, M. Cekmen, A. Neyal, S. Gursay, O. Erel, A. Balat, Plasma nitrite levels, total antioxidant status, total oxidant status, and oxidative stress index in patients with tension-type headache and fibromyalgia, *Clin. Neurol. Neurosurg.* 115 (2013) 736–740.
- [12] H. Aebi, Catalase *in vitro*, *Methods Enzymol.* 105 (1984) 121–126.
- [13] P. Kakkar, B. Das, P.N. Viswanathan, A modified spectrophotometric assay of superoxide dismutase, *Indian J. Biochem. Biophys.* 21 (1984) 130–132.
- [14] D.G. Hardie, F.A. Ross, S.A. Hawley, AMPK: a nutrient and energy sensor that maintains energy homeostasis, *Nat. Rev. Mol. Cell Biol.* 13 (2012) 251–262.
- [15] S.B. Wu, Y.H. Wei, AMPK-mediated increase of glycolysis as an adaptive response to oxidative stress in human cells: implication of the cell survival in mitochondrial diseases, *Biochim. Biophys. Acta* 1822 (2012) 233–247.

- [16] O.K. Melemedjian, M.N. Asiedu, D.V. Tillu, R. Sanoja, J. Yan, A. Lark, A. Khoutorsky, J. Johnson, K.A. Peebles, T. Lepow, N. Sonenberg, G. Dussor, T.J. Price, Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain, *Mol. Pain* 7 (2011) 70.
- [17] K. Cao, A. Zheng, J. Xu, H. Li, J. Liu, Y. Peng, J. Long, X. Zou, Y. Li, C. Chen, J. Liu, Z. Feng, AMPK activation prevents prenatal stress-induced cognitive impairment: modulation of mitochondrial content and oxidative stress, *Free Radic. Biol. Med.* 75 (2014) 156–166.
- [18] S.B. Wu, Y.T. Wu, T.P. Wu, Y.H. Wei, Role of AMPK-mediated adaptive responses in human cells with mitochondrial dysfunction to oxidative stress, *Biochim. Biophys. Acta* 1840 (2014) 1331–1344.
- [19] K. Takeuchi, Y. Morizane, C. Kamami-Levy, J. Suzuki, M. Kayama, W. Cai, J.W. Miller, D.G. Vavvas, AMP-dependent kinase inhibits oxidative stress-induced caveolin-1 phosphorylation and endocytosis by suppressing the dissociation between c-Abl and Prdx1 proteins in endothelial cells, *J. Biol. Chem.* 288 (2013) 20581–20591.
- [20] Z. Lu, X. Xu, X. Hu, J. Fassett, G. Zhu, Y. Tao, J. Li, Y. Huang, P. Zhang, B. Zhao, Y. Chen, PGC-1  $\alpha$  regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload, *Antioxid. Redox Signal.* 13 (2010) 1011–1022.
- [21] D. Marmolino, M. Manto, F. Acquaviva, P. Vergara, A. Ravella, A. Monticelli, M. Pandolfo, PGC-1 $\alpha$  down-regulation affects the antioxidant response in Friedreich's ataxia, *PLoS One* 5 (2010) e10025.
- [22] D.J. Clauw, Fibromyalgia: a clinical review, *JAMA* 311 (2014) 1547–1555.
- [23] M.E. Bote, J.J. García, M.D. Hinchado, E. Ortega, Inflammatory/stress feedback dysregulation in women with fibromyalgia, *Neuroimmunomodulation* 19 (2012) 343–351.
- [24] R. Alok, S.K. Das, G.G. Agarwal, L. Salwahan, R. Srivastava, Relationship of severity of depression, anxiety and stress with severity of fibromyalgia, *Clin. Exp. Rheumatol.* 29 (2011) S70–S72.
- [25] L. Arranz, M.A. Canela, M. Rafecas, Relationship between body mass index, fat mass and lean mass with SF-36 quality of life scores in a group of fibromyalgia patients, *Rheumatol. Int.* 32 (2012) 3605–3611.
- [26] B.L. Loevinger, D. Muller, C. Alonso, C.L. Coe, Metabolic syndrome in women with chronic pain, *Metabolism* 56 (2007) 87–93.
- [27] R. de Cabo, S. Fürer-Galbán, R.M. Anson, C. Gilman, M. Gorospe, M.A. Lane, An in vitro model of caloric restriction, *Exp. Gerontol.* 38 (2003) 631–639.